These Two Medical Stocks Are Screaming Sell — Here's What Happened

Insulet (PODD) stock crashed Wednesday — alongside fellow medtech Medline (MDLN) — after lowering sales guidance for its body-worn insulin pump, Omnipod, in the back half of the year. The company now expects sales to grow 20% to 22% this year, in constant currency, down from its prior view for 21%-23% growth. On a reported based, Insulet projects sales growth…